PROMISE-1 and PROMISE-2 sub-analyses

Key messages

• Patients seek preventative treatments that deliver a rapid onset of clinical benefit.
• Eptinezumab provides rapid and sustained preventative migraine relief for patients who experience both episodic and chronic migraine.
• Eptinezumab prevents the occurrence of migraine from day one following intravenous administration and is sustained for up to 12 weeks in the majority of patients.